微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 19.16% | -4.37% | 5.26% | 139/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 18.2% | -2.9% | -3.09% | 143/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 18.78% | -22.1% | -2.02% | 136/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 19.17% | -18.4% | -4.32% | 134/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 20.04% | -19.94% | 6.88% | 134/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 18.75% | -31.67% | -22.25% | 132/157 | 31.96% | 艾力斯医药科技 | 96.74% | 行业排名> |
| 2024-12-31 | 24.11% | -18.33% | 2.63% | 129/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 23.5% | -19.23% | -6.13% | 131/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.03% | -15.94% | -8.77% | 129/157 | 33.12% | 百利天恒药业 | 97.99% | 行业排名> |
| 2024-03-31 | 27.44% | -12.57% | -7.07% | 121/157 | 51.76% | 百利天恒药业 | 98.92% | 行业排名> |
| 2023-12-31 | 29.52% | 8.73% | 1.49% | 120/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 29.09% | 11.78% | -2.3% | 121/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 29.78% | 14.52% | -5.11% | 121/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 31.38% | 14.76% | 15.57% | 115/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.15% | 0.43% | 4.34% | 126/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 26.02% | -7.21% | 0.09% | 122/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 26% | -11.22% | -4.91% | 128/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 27.34% | -5.95% | 1.14% | 116/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 27.04% | -10.52% | -3.6% | 131/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 28.05% | -3.31% | -4.24% | 117/157 | 46.77% | 艾力斯医药科技 | 99.41% | 行业排名> |
| 2021-06-30 | 29.29% | 4.38% | 0.73% | 125/157 | 47.23% | 艾力斯医药科技 | 98.7% | 行业排名> |
| 2021-03-31 | 29.08% | 2.59% | -3.77% | 107/157 | 54.13% | 艾力斯医药科技 | 99.4% | 行业排名> |
| 2020-12-31 | 30.22% | -9.64% | 4.17% | 126/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 29.01% | -8.42% | 3.38% | 105/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 28.06% | -11.01% | -1% | 116/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 28.34% | -12.07% | -15.24% | 98/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 33.44% | 10.98% | 5.58% | 111/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 31.67% | 13.41% | 0.46% | 92/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 31.53% | 13.18% | -2.18% | 98/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 32.23% | 12.88% | 6.97% | 87/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 30.13% | 7.3% | 7.89% | 113/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 27.93% | 2.98% | 0.26% | 90/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.86% | 1.43% | -2.44% | 94/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 28.56% | 5.85% | 1.68% | 88/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 28.08% | 12.59% | 3.55% | 106/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.12% | 12.23% | -1.26% | 83/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 27.46% | 19.9% | 1.81% | 83/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.98% | 10.51% | 8.16% | 70/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 24.94% | 7.23% | 3.21% | 98/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 24.17% | 8.25% | 5.49% | 72/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 22.91% | 6.64% | -6.16% | 82/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 24.41% | 6.02% | 4.95% | 67/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |